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Human chorionic gonadotropin levels in serum
and follicular fluid are correlated with body
mass index rather than the route
of administration of purified hCG in ART cycles

Leyla MOLLAMAHMUTOĞLU1

Aim: To investigate hCG levels in follicular fluid and serum after intramuscular (IM) or
subcutaneous (SC) administration of purified hCG, and their association with oocyte maturation
and body mass index (BMI) in women undergoing IVF-ET.
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Materials and Methods: The study included 160 infertile women that were recruited between
April and June 2007. Standard-dose long IVF protocols were used for ovulation induction. SC or
IM injections were used to administer hCG. BMI, oocyte maturity, and serum and follicular fluid
hCG levels were the main outcome measurements.
Results: hCG levels in serum and follicular fluid in the 2 groups were similar. A negative
correlation was observed between BMI and intrafollicular serum hCG levels. Mature oocyte counts
were similar in the 2 groups. No correlation was observed between BMI and oocyte maturation. A
negative correlation between BMI, and serum and follicular fluid hCG levels was more prominent
in the IM group than in the SC group. Pregnancy rates were lower in the IM group.
Conclusions: Similar hCG levels were observed in the 2 groups. SC administration should be
preferred over IM injection, as it is less painful for the patient and is easily administered. Serum
and follicular fluid hCG levels were correlated with BMI, rather than the route of hCG
administration.
Key Words: Ovulation induction, IVF cycles, purified hCG, BMI, SC injection of hCG

ART sikluslarında, intrafolliküler ve serum hCG Düzeyleri,
purifiye hCG’nin veriliş yolundan çok hastaların
vücut–kitle indeksi ile koreledir
Amaç: IVF-ET uygulanan hastalarda intramuskuler (IM) veya subkutan (SC) uygulanan pürifiye
human koryonik gonodotropin`in (hCG) serum ve follikuler sıvı düzeylerinin oosit matürasyonu
ve vücut kitle indeksi (body mass index - BMI) ile korelasyonunu değerlendirmektir.
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Yöntemler: Nisan - Haziran 2007 tarihleri arasında Yardımcı Üreme Teknikleri Ünitesine
başvuran 160 infertil kadın çalışmaya alındı.Tüm indüksiyon protokollerinde standart doz uzun
protokol uygulandı. Ovulasyonu tetiklemek amacıyla alt abdomene SC veya kalçadan IM yolla
hCG uygulandı. İntra folliküler ve serum hCG düzeyleri, oosit matüritesi ve BMI takip
parametreleri olarak belirlendi.
Bulgular: IM ve SC grupların serum ve intrafolliküler hCG düzeylerinde fark izlenmedi. BMI ile
serum ve intrafolliküler hCG düzeyleri arasında negatif korelasyon izlendi.Her iki grupta benzer
düzeyde matür oosit izlendi. BMI ile oosit matürasyonu arasında korelasyon izlenmedi. BMI ile
serum ve intrafolliküler hCG düzeyleri arasındaki negatif korelasyon IM grupta daha yüksek
olarak izlendi. IM grup SC gruptan daha düşük gebelik oranlarına sahipti.
Sonuç: IM ve SC grupları arasında hCG düzeyleri yönünden benzer sonuçlar elde edilmiştir. SC
yol kulanım kolaylığı ve daha az ağrılı olması nedeniyle hastalar için tercih sebebi olabilir. İntra
folliküler ve serum hCG düzeyleri ilacın kullanım seklinden çok BMI ile koreledir.

sevtapkilic@gmail.com

Anahtar Sözcükler: Ovulasyon indüksiyonu, IVF siklusları, pürifiye hCG, vücut kitle indeksi,
subkutan hCG enjeksiyonu
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Introduction
The mid-cycle luteinizing hormone (LH) surge is
necessary for maturation of the oocyte and initiation
of follicular luteinization. During IVF, a supraphysiological dose (10,000 IU) of hCG is given to
mimic the effects of the natural LH surge. The
administration of hCG at the end of a stimulation
phase of gonadotropins triggers maturation of the
cumulus-oocyte complex and allows the resumption
of meiosis in the oocyte. Decreased periovulatory
hCG concentrations are reported to be associated
with lower fertilization rates (1). The purified form of
hCG is usually given via the intramuscular (IM)
route, but subcutaneous (SC) administration has also
been described (2).
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The aim of the present prospective study was to
evaluate and compare the effects of SC and IM
administration of hCG on serum and follicular fluids
hormone levels, oocyte maturation, and IVF
outcome, and their association with BMI in women
undergoing IVF-ET using r-FSH and ICSI.
The study was based on the following questions:
1. Is there any difference in serum and follicular
fluid hCG levels between IVF patients that receive
purified hCG via the IM and SC route (Pregynl
10,000 IU) to stimulate ovulation?
2. Does the administration of hCG via IM and SC
routes have any effect on parameters such as oocyte
maturation, fertilization rate, embryo grade, and
pregnancy outcome?

In fact, SC administration of hCG has been used
in both Europe and North America for ovulation
induction and IVF treatment. The SC route of
administration, which allows self-administration by
the patient, has previously been used (3). This is
especially relevant when hCG administration, which
is usually timed, is to be given late at night and
nursing staff must be available outside normal office
hours to administer an IM injection.

3. Is there any correlation between BMI, and
serum and follicular fluid hCG levels in terms of drug
distribution?

Drug distribution and metabolism in the body are
dependent on the amount of adipose tissue, as well as
the route of administration and rate of plasma
clearance (4). The pharmacokinetic behavior of hCG
may also be affected by obesity. In general, a larger
distribution volume results in a lower serum
concentration (5). The body mass index (BMI) is
widely used in epidemiological studies as a good
indicator of adiposity (6). In a prospective cohort
study, Salha et al. concluded that a high BMI is
detrimental to the success of IVF treatment and has a
significant influence on the distribution and
metabolism of hCG (7). Elkind-Hirsch et al. also
reported that the highest levels of hCG were
measured in women with the lowest BMI (3).

The study included 113 women aged 19-39 years
recruited from the Zekai Tahir Burak Women’s
Hospital Assisted Reproduction Clinic that were
undergoing the first or second IVF cycle between
April 2007 and June 2007. Infertility among the
patients was attributable to tubal factors (including
endometriosis) (n = 13), unexplained infertility (n =
64), sub-fertile male factor infertility (n = 36) (≥ 5
total progressive motile spermatozoa per milliliter).
Ethical approval was obtained from the local research
ethics committee prior to commencement of the
study and written informed consent was obtained
from all the participants.

Although the pharmacokinetics following both
routes of administration have been compared (3,6,810), the results obtained are inconsistent. Studies to
date have been inconclusive as to the effect of BMI on
serum concentrations of hCG in predicting the
outcome of IVF treatment, in terms of biochemical
and clinical pregnancy rates (4).

- Patients with severe male factor infertility (< 5
total progressive motile spermatozoa per
milliliter and allowing for TESE);
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4. Is SC administration of hCG preferable in terms
of patient compliance and ease of administration, and
are there potential side-effects?
Methods

The exclusion criteria were as follows:
- Patients older than 39 years old;

- Patients with an endocrine disorder
(hyperthyroidism
or
hypothyroidism,
hyperprolactinemia, or premature ovarian
failure);

Vol: 39

hCG levels are correlated with BMI in ART cycles

No: 3

- Diminished ovarian reserve (FSH > 10 IU/ml);
- Any evidence of any clinically relevant systemic
disease (e.g., IDDM);
- More than 3 previous failed IVF cycles or an
IVF cycle canceled because of poor response to
gonadotropins;
- Prior documentation of intolerance or allergy to
any gonadotropin;
- A uterine anomaly or uterine fibroids and
hydrosalpinges.
Superovulation Protocol (Figure 1)
All patients were pretreated with 50 mg estradiol
+ 500 mg norgestrel as oral contraceptive (Desolett,
Schering-Plough) for 18 days, starting day 3 of the
cycle. Pituitary suppression with a GnRHagonist–Lucrin flakon (Abbott, Cedex, İstanbul)–was
initiated on cycle day 18 at the dose of 1 mg/day SC
injection into the thigh or arm. On day 2 of menses a
baseline ultrasound (US) was performed to document
that the ovaries were quiescent. Documentation of
pituitary down-regulation was indicated by an
estradiol level < 50 pg/ml and an LH level < 5 IU/ml.
The stimulation cycle began by using r-FSH
(Gonal-F, Serono, İstanbul) at the dose of 225 IU/day,
which was administered for 3 days. After starting rFSH, the Lucrin flakon dose was decreased to 0.5
mg/day (Figure 1). Estradiol monitoring and US were
performed according to standard IVF clinical
practice. When a minimum of 3 follicles exceeded 16
mm in average diameter, an ovulatory dose of
purified hCG ((Profasi 5000 IU, Serono, İstanbul)
was given by IM or SC injection to all the patients
(Figure 1).

All serum samples and follicular fluids were
collected on the same day as oocyte retrieval.
Follicular fluid was collected from the first mature
follicle aspirated, using media-free collection tubes.
The number of cells of each embryo and embryo
qualities were documented. Embryos were
transferred 3 days after retrieval and a maximum of 3
embryos were replaced into each patient’s uterus.
Luteal phase support was prescribed vaginally
beginning on the day after egg retrieval (Crinone 8%;
Serono, İstanbul, 400 mg/day) and continued until 14
days after retrieval, at which time a quantitative
measurement of the hCG level was obtained.
Data regarding the number of oocytes obtained,
serum hCG level, follicular fluid hCG level,
fertilization rate, number of embryos transferred,
pregnancy rate (+ hCG/ET), and hCG ratio (follicular
fluid hCG/serum hCG) were recorded for each
patient. BMI was calculated for each patient using her
weight and height (kg/m2).
Hormone Assays
Serum and follicular fluid aspirates were stored at
–20 °C after 10 min of centrifugation at 3000 RPM.
Estradiol and hCG levels were measured using an
automated, electrochemiluminescence (ECLIA E-

beta hCG

ET

OPU

rFSH
225 IU

HCG (10,000 IU)

< 5 IU/ml

Subjects were assigned, using a computergenerated random numbers table, to receive IM or SC
hCG on the day after the last dose of gonadotropins.
The SC injection of hCG was self-administered in the
lower abdomen with a 5/8-inch 27-gauge needle. The
volume of diluent was 1 ml for both the SC and IM
injections. Vaginal oocyte retrieval was performed
under US guidance 36 h after hCG injection. The
oocytes were then fertilized using ICSI technology.

US, E2, LH

< 50 pg/ml

June 2009

Day of mens.
3

2

18
O.C

GNRHa (Lucrin) 1 mg/day

3 4 5 6 7 8 9 10
GNRHa 0.5 mg/day

36h

3Days

11 days

Vag. Progesterone

Figure 1.Superovulation protocol.
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170, ROCHE) system with a sensitivity for hCG < 0.1
mIU/ml and linear interassay precision of 0.1-10,000
mIU/ml.
Statistical Analyses
To compare differences in age, BMI, hormone
measurements (serum hCG 36 h after administration,
serum estradiol levels on the day of hCG
measurement), duration and total r-FSH treatment
dose, number of oocytes retrieved, and oocyte
maturation between the SC and IM groups, unpaired
t tests were used. Spearman’s and Pearson’s productmoment correlation tests were used to determine the
relationships between BMI, and serum and follicular
hCG concentration, and then linear regression
analysis was used for positive correlations. The chisquared test was used to determine the difference
between the presence and absence of outcome
variables (e.g., clinical pregnancy). A P value < 0.05
was regarded as statistically significant.
Results
The IM group contained 56 women and 57
women were in the SC group. Baseline and cycle
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characteristics in the 2 groups are depicted in Table 1.
Mean age and mean BMI were similar in the 2 groups
(mean age: 30 years; mean BMI: 25.5). All BMIs were
between 19 and 36. There were no significant
differences between the groups in terms of cycle
length, number of antral follicles, total gonadotropin
usage, peak E2 level before hCG injection, number of
oocytes retrieved, percentage of oocytes with normal
fertilization, or pregnancy rates (Table 1).
Serum and follicular hCG levels in the SC group
were higher than in the IM group, but the differences
were not significant (279.3 ± 231. vs. 222.4 ± 103.3
mIU/ml, P = 0.10 and 151.3 ± 108.2 vs. 134.9 ± 85.4
mIU/ml, P = 0.37, respectively). With regard to the
ratio of follicular fluid hCG level to serum hCG level,
there was not a significant difference between the
pregnant (P = 0.63) and non-pregnant patients (0.58)
(P = 0.417).
A statistically significant difference (P = 0.14) was
not observed between the pregnancy rates in the IM
group (35.7%) and the SC group (49.1%) (Table 1).
A negative correlation between BMI, and
intrafollicular and serum hCG levels (r = −0.27, r =
−0.24) was observed in all the patients in both groups.

Table 1. Basal hormone levels and demographic characteristics of the patients.
Baseline and cycle characteristics between groups
Variable

IM (n=56)

SC (n = 57)

(p)

(t)

Age (years)
2
BMI (kg/m )
Duration of infertility (years)
2
Baseline E levels (pg/ml)
Baseline FSH levels (mIU/ml)
Total number of antral follicles
Duration of r-FSH (d)
Total dose of r-FSH (IU)
Serum E2 (pg/ml) day of hCG
Serum hCG levels (mIU/ml) on day of OPU
Total number of oocytes retrieved
% of oocytes suitable for ICSI (fert. rate)
2
Total number of mature oocytes (m )
Total number of embryos
Follicular fluid hCG level (mIU/ml) on day of OPU
Biochemical pregnancy outcome (+hCG/ET)
hCG ratio (fol. hCG/serum hCG)

30.0 ± 5.4
25.4 ± 4.0
7.8 ± 5.0
45.7 ± 18.6
6.7 ± 1.9
9.4 ± 4.1
9.6 ± 1.3
2349.9 ± 1059.3
2182.4 ± 913.2
222.4 ± 103.4
10.2 ± 5.2
77.0± 30.7
8.0 ± 4.8
5.1 ± 3.2
134.9 ± 85.4
20/56 (35.7%)
0.58 ± 0.2

30.6 ± 4.7
25.6 ± 3.0
9.5 ± 5.2
41.2 ± 12.7
6.9 ± 1.9
10.4 ± 4.1
9.7 ± 1.7
2266.4 ± 930.8
2132.9 ± 818.8
279.3 ± 237.1
9.2 ± 4.2
72.7 ± 27.4
7.4 ± 3.8
5.1 ± 3.6
151.3 ± 108.2
28/57 (49.1%)
0.63 ± 0.3

0.571
0.572
0.843
0.500
0.499
0.089
0.089
0.845
0.844
0.194
0.750
0.657
0.657
0.763
0.102
0.140
0.454

−0.6
−0.6
−0.2
−0.7
−0.7
−1.7
−1.7
−0.2
−0.2
-1.3
-0.3
0.4
0.4
0.3
−1.6

*A P value < 0.05 was regarded as statistically significant.
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Table 3. Correlation between BMI in the 2 groups based on
Spearman’s correlation test. There was a significant
negative correlation between BMI, and serum and
follicular fluid hCG levels in the IM group. There were no
significant correlations between BMI, and oocyte
maturation, fertilization rate, or pregnancy rate in either
group.

As BMI increased, serum and follicular fluid hCG
levels decreased (P = 0.008, P = 0.003) (Table 2).
A significant negative correlation between BMI,
and serum and follicular fluid hCG levels was
observed in the IM group (IM group: n = 56,
Spearman’s correlation: r = −0. 34, P = 0.009; r = −0.
36, P = 0.006 vs. SC group: n = 57; Spearman’s
correlation: r = −0.12, P = 0.37; r = −0.17, P = 0.20)
(Table 3). A significant correlation was not observed
between BMI and oocyte maturation (r = −0.05; P =
0.53) (Table 3). There was a strong negative
correlation between BMI and follicular fluid hCG
level in the IM group, but in the SC group there was
a weak negative correlation (Figure 2).

BMI
IM GROUP
(n = 56)

Foll hCG
Serum hCG
M2 oocytes
Fert. ratio
Pregnancy

There was a statistically significant trend in
decreasing serum and follicular fluid hCG levels with
increasing BMI in IM group in the linear regression
analysis (P = 0.001) (Table 4).

SC GROUP
(n = 57)

(r)

(P)

(r)

(P)

−0.36
−0.34
−0.10
0.045
−0.05

0.006
0.009
0.44
0.74
0.68

−0.12
−0.17
−0.11
−0.03
−0.19

0.37
0.20
0.41
0.77
0.88

*Correlation was significant at the 0.01 level (2-tailed).

Significant local adverse effects were not observed
in the SC group; only 2 patients experienced
inflammation at the injection site and 9 patients had
skin tenderness in the SC group compared to 6 in the
IM group. All the observed symptoms disappeared
within 24 h.

provide this stimulus. There have been several studies
on the pharmacokinetics of hCG administration
(3,6,8-10). Weissman et al., studying the
pharmacokinetics of a single IM versus SC dose of
hCG, observed a similar profile, with the highest hCG
concentrations achieved with a dose of 10,000 IU
administered subcutaneously. They concluded that SC
injection of hCG for induction of ovulation is a simple
and safe method, which might result in higher patient
tolerance of infertility treatment (10). The advantages
of SC injection of hCG are obvious. The International
Recombinant Human Chorionic Gonadotropin Study

Discussion
The complex process of oocyte maturation and
ovulation requires a timely LH surge in the natural
cycle. In the stimulated cycle, hCG is administered to

Table 2. When we look at the correlations between BMI and serum and follicular hCG levels, a
negative correlation was found between BMI with intrafollicular and serum hCG levels in all
patients, regardless of adminstration route. And these correlations are statistically significant
(p=0.008;p=0.003).

bmi

Serum
hcg

folhcg

bmi

opuhcg

folhcg

1

-0.247(**)
0.008
113

-0.273(**)
0.003
113

1

0.559(**)
0.000
113
1

Pearson Correıation
Sig. (2-tailed)
N

113

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correıation
Sig. (2-tailed)
N

-0.247(**)
0.008
113
-0.273(**)
0.003
113

113
0.559(**)
0.000
113

113

** Corelation is significant at the 0.01 level (2 tailed)
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600.00

0.00

follicular hCG

200.00

400.00
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follicular hCG
Dot/Lines show Means

I.M

S.C

35.00

BMI

30.00

25.00
n = 57
n = 56

20.00
0.00

200.00

400.00

600.00

follicular hCG

0.00

200.00

400.00

600.00

follicular hCG

Figure 2. There was a strong negative correlation in the IM group between BMI and follicular fluid hCG level, whereas in the SC group there
was a weak negative correlation.

Group suggested that both urinary hCG and
recombinant hCG were effective in ovulation
induction when administered via the SC route and that
no statistically significant differences were observed
between the treatment groups in terms of the primary
efficacy endpoints (12). With SC hCG administration
there is no need for the patient to visit a clinic or have
a partner be responsible for injections. Jones et al.
reported that SC self-administered hCG in males with
hypogonadotropic hypogonadism is safe and produces
comparable levels of serum and salivary testosterone
to that administered via the IM route (13).
394

The present study showed that 36 h after IM or SC
injection of purified hCG (10,000 IU) serum and
follicular fluid hCG concentrations were similar and
that there were no differences between the 2 groups’
cycle length, total gonadotropin usage, peak E2 level
before hCG injection, number of oocytes retrieved,
number of M2 oocytes, fertilization rates, or
pregnancy rates. Serum and follicular fluid hCG
levels in the SC group were slightly higher than in the
IM group, but the difference was not statistically
significant. Stelling et al. demonstrated that SC
administration of purified hCG during IVF for
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Table 4. Linear Regression Analysis. There was a statistically significant trend in decreasing serum and follicular fluid hCG levels with
increasing BMI in IM group (P = 0.001).
Coefficients
Unstandardized
Coefficients
Group

Model

i.m

1

s.c.

1

(Constand)
bmi
(Constand)
bmi

Standardized
Coefficiets

B

Std. Error

347.003
-8.33
307.191
-6.022

67.680
2.626
122.016
4.736

Beta

t

Sig.

-0.169

5.127
-3.173
2.518
-1.272

0
0.002
0.015
0.209

N

-0.396

Residuals Statsitics
Group
i.m.

s.c.

Minimum

maximum

Mean

Std.deviation

Predicted Value
Residual
Std. Predicted Value
Std. Residual

44.537
-2.669
-1.673

187.5633
-132.424
1.554
2.072

134.925
164.05403
0
0

33.86662
0
1
0.991

Predicted value
residual
Std.predicted value
Std. Residual

106.4595
-108.653
-2.572
-1.019

182.5179
449.0593
1.625
4.211

153.0719
0
0
0

18.12031
105.67643
1
0.991

56
78.44414 56
56
56
57
57
57
57

a. Dependent Variable: folhcg

follicular and oocyte maturation achieves higher
serum and follicular fluid hCG levels at the time of
oocyte retrieval than the IM route. Their large
retrospective study of 600 cycles reported no
difference in pregnancy rates (6). Another group (8)
studied hCG levels at 12 and 36 h after hCG injection
to induce oocyte maturation during IVF cycles, and
reported that serum levels of hCG were significantly
higher in women that received IM injection than in
those that received SC injection, especially at 12 h
after injection. In contrast, using the same model, no
difference in the serum concentration of hCG was
observed at 12 h (3) or 24 h (9) after injection when
the study was repeated. It was also noted that the
difference in serum hCG level between the women
that received IM and SC administration was smaller
at 36 h.
Nagata et al. concluded that the ratio of the level of
hCG in the follicular fluid to the level of serum hCG
was a good marker for ovarian responsiveness and
subsequent pregnancy. They reported that the ratio of

the level of serum hCG must be at least 0.46 to be
adequate for pregnancy (11). We observed that the
mean hCG ratio in the SC group was 0.62 versus 0.58
in the IM group (P = 0.45). With regard to the ratio
of follicular fluid hCG level to serum hCG level, we
did not observe a significant difference between
pregnant (0.63) and non-pregnant patients (0.58) (P
= 0.417).
Obese women have a larger volume of distribution
than non-obese women, and this may lead to a lower
serum hCG concentration after drug administration
(5). Elkind-Hirsh et al. (2001) observed a strong
negative correlation between serum hCG levels and
BMI. The highest levels of hCG were measured in
women with the lowest BMI (3). Our results are
consistent with studies that reported a negative
correlation between BMI, and intrafollicular and
serum hCG levels in all patients, regardless of the
route of administration. As BMI increased in the
present study, serum and follicular fluid hCG levels
decreased. A correlation between BMI, and oocyte
395
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maturation and fertilization rates was not noted in
the present study. We also observed a significant
negative correlation between BMI, and serum and
follicular fluid hCG levels in the IM group; however,
in the SC group we observed a weak correlation
between BMI, and serum and follicular fluid hCG
levels.
Carrel et al. (2001) reported an inverse correlation
between BMI and intrafollicular hCG concentration
(1). Their data clearly indicate a poor prognosis for
IVF patients with a BMI > 30. Chan et al. noted
generally higher bioavailability of the drug following
IM administration; however, they also observed
lower bioavailability of hCG in obese women,
irrespective of the route of administration (2).

Turk J Med Sci

In conclusion, the advantages of selfadministering hCG via the SC route are obvious;
there is no need for women to visit a clinic or a nurse
late at night, and a couple can now take care of all
their hormone injections during a treatment cycle. In
non-obese patients SC administration of purified
hCG does not compromise cycle outcome, and
increases convenience and flexibility in the treatment
program, and it is more cost effective than
recombinant forms of hCG. Based on the present
study’s results, BMI, rather than the route of hCG
administration, determines circulating levels of hCG
and, ultimately, oocyte exposure to gonadotropin for
final maturation.
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